We also had a 40% rise in November prior to the Phelan-McDermid Syndrome results which were positive, but the company has been saying for some time that NNZ-2591 is the better compound, and these are open label compared to NNZ-2256 which was a blinded placebo-controlled trial in Phase-2. It shows that the preclinical data is stronger, and the company wants to accelerate the pathway to a registrational study that is placebo and double blinded. It is a bold move because the Placebo affect could impact the P3 but the company thinks the efficacy data is strong enough to warrant this for an accelerated development time.
- Forums
- Charts
- NEU chart
We also had a 40% rise in November prior to the Phelan-McDermid...
-
- There are more pages in this discussion • 260 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add NEU (ASX) to my watchlist
(20min delay)
|
|||||
Last
$14.05 |
Change
-0.510(3.50%) |
Mkt cap ! $1.795B |
Open | High | Low | Value | Volume |
$14.38 | $14.42 | $13.94 | $6.419M | 454.6K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 500 | $13.99 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$14.07 | 6644 | 4 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 500 | 13.990 |
1 | 300 | 13.970 |
1 | 400 | 13.960 |
3 | 2997 | 13.950 |
1 | 1828 | 13.930 |
Price($) | Vol. | No. |
---|---|---|
14.070 | 6644 | 4 |
14.080 | 323 | 2 |
14.100 | 1828 | 1 |
14.130 | 1828 | 1 |
14.150 | 1828 | 1 |
Last trade - 16.10pm 04/10/2024 (20 minute delay) ? |
Featured News
NEU (ASX) Chart |